✦ LIBER ✦

T cell function in chronic myeloid leukemia and its treatment with tyrosine kinase inhibitors—Clues from and for sarcoidosis

✍ Scribed by Maqsood Punekar; Jecko Thachil; Rahuman Salim; Sara Watmough; Richard E. Clark

Book ID: 104040927
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 87 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2008.11.032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stem cell transplantation for patients w

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I

✍ Nikolai Velev; Jorge Cortes; Richard Champlin; Dan Jones; Gabriela Rondon; Sergi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

Rapid and sensitive allele-specific (AS)

Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors

✍ Gonzalo Manrique Arechavaleta; Vanesa Scholl; Verónica Pérez; Roberta Bittencour 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 297 KB

Novel tyrosine kinase inhibitor therapy

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia : No evidence for increased transplant-related toxicity

✍ Elias Jabbour; Jorge Cortes; Hagop Kantarjian; Sergio Giralt; Borje S. Andersson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

## Abstract ## BACKGROUND. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate. It is unknown whether the use of these NTKI

Prior treatment with the tyrosine kinase

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

✍ Shimoni, A; Leiba, M; Schleuning, M; Martineau, G; Renaud, M; Koren-Michowitz, M 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB

Restricted access to second generation t

Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study

✍ Paolo Gallipoli; Pat Shepherd; David Irvine; Mark Drummond; Tessa Holyoake 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB